What Researchers Did
Researchers presented a case study of a 63-year-old man with refractory bilateral leg ulcers due to chronic limb-threatening ischemia, who was treated with 20 sessions of the Rheocarna adsorptive blood-purification device alongside wound care and hyperbaric oxygen.
What They Found
The 63-year-old patient, ineligible for standard revascularization, underwent 20 Rheocarna treatment sessions. These sessions, combined with wound care and hyperbaric oxygen, led to improved circulation and ulcer healing, successfully preventing amputation.
What This Means for Canadian Patients
For Canadian patients with chronic limb-threatening ischemia and refractory ulcers who are not candidates for revascularization, this case suggests a potential alternative treatment. While Rheocarna is not yet approved in Canada, it offers a glimpse into future therapies that could prevent amputations in similar challenging cases.
Canadian Relevance
This study has no direct Canadian connection as the research was conducted in Japan and the device, Rheocarna, is approved there but not in Canada.
Study Limitations
A significant limitation is that this was a single case report, meaning its findings cannot be generalized without further larger-scale studies.